This site is intended for healthcare professionals only.

Real-World Application of CGM Technology to Improve Diabetes Management in Primary Care

Do you feel confident in your ability to integrate continuous glucose monitoring (CGM) technology into clinical practice?

Apply your CGM knowledge and put your clinical decision-making and patient communication skills to the test with our real-world case studies!

Explore how best to utilize CGM to enhance diabetes management and optimize patient outcomes.

CME available

1.0 AMA PRA Category 1 Credits™ available (look for the badge)

Interested in learning more? Listen to Dr. Joseph Henske as he discusses the activities and goals of this CME program.

Register now

Learning Objectives

Following completion of this independent educational program, you will be able to: 

  • Identify patients who are appropriate candidates for CGM devices 
  • Compare available CGM technologies based on individual patient characteristics 
  • Adapt clinical decision making by using patients’ CGM device readouts 
  • Apply shared decision-making tools when evaluating barriers to CGM usage and adherence 
  • Modify patient education techniques for utilization in time-limited primary care appointments 

About the Program

This comprehensive educational program includes CME-accredited interactive case studies that focus on clinical reasoning and decision-making skills, and patient communication and education. In addition, the CME-accredited patient-provider interview showcases optimal shared decision-making techniques to guide patient care with CGM devices. 

Target Audience

This program is aimed at US-based primary care physicians (PCPs) who are looking to improve their knowledge and skills in CGM technology for patients with T2D.

Program Activities

Case Studies

Person on laptop with medical imagery overlaid © woravut/stock.adobe.com
CME available

Put your clinical decision-making skills to the test in our interactive case studies that examine crucial factors for incorporating CGMs into a patient-centric approach to manage diabetes.

  • Earn up to 0.75 AMA PRA Category 1 Credits™
Get started

Patient Interview

Close up black woman listening to doctor in clinic © Seventyfour/Stock.adobe.com
CME available

Join the conversation between our diabetes expert and a patient living with diabetes, as they provide guidance on how to improve communication on managing diabetes with a CGM. 

  • Earn up to 0.25 AMA PRA Category 1 Credits™
Get started

Frequently Asked Questions

Concept image of doctor holding question mark © atipong/stock.adobe.com

Discover insights from our experts on the most pressing questions from learners!

View now

Learning Objectives

Following completion of this independent educational program, you will be able to: 

  • Identify patients who are appropriate candidates for CGM devices 
  • Compare available CGM technologies based on individual patient characteristics 
  • Adapt clinical decision making by using patients’ CGM device readouts 
  • Apply shared decision-making tools when evaluating barriers to CGM usage and adherence 
  • Modify patient education techniques for utilization in time-limited primary care appointments 

About the Program

This comprehensive educational program includes CME-accredited interactive case studies that focus on clinical reasoning and decision-making skills, and patient communication and education. In addition, the CME-accredited patient-provider interview showcases optimal shared decision-making techniques to guide patient care with CGM devices. 

Target Audience

This program is aimed at US-based primary care physicians (PCPs) who are looking to improve their knowledge and skills in CGM technology for patients with T2D.

Meet the Faculty

Joseph A. Henske

Program Director

Joseph A. Henske, MD

UAMS Health 
Little Rock, AR
United States 

View Biography
Vivian Fonseca

Faculty Member

Vivian Fonseca, MD, FRCP

Tulane University School of Medicine
New Orleans, LA
United States 

View Biography
Anne Peters

Faculty Member

Anne Peters, MD

Keck School of Medicine, USC
Los Angeles, CA
United States 

View Biography

Accreditation

In support of improving patient care, this program has been planned and implemented by the Postgraduate Institute for Medicine and Springer Healthcare IME. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the program. 

Planning Committee

In addition to the expert faculty, the Postgraduate Institute for Medicine and Springer Healthcare IME planners and staff include Holly Keatts, Judith Mitchek, Maria Glukhovsky, Elizabeth Samander, Alessandra Geffner-Smith, Jennifer Jett, and Kristen Rogers. The Planning Committee has no financial relationships to disclose.

All relevant financial relationships of the faculty have been mitigated.

Like this content? Share with a colleague

X-twitter Linkedin Facebook Envelope
© 2025 Springer Healthcare Limited. Part of Springer Nature Group.
X-twitter Linkedin Instagram Youtube
This site is intended for healthcare professionals only.
Funding

This activity is supported by an independent educational grant from Abbott.

Contact Us

Email: IME@springer.com

Springer Healthcare IME
1 FRD Drive, One New York Plaza
New York, 10004,
United States

Privacy Policy
Terms & Conditions
Manage Cookie Preferences
Joseph A. Henske

Program Director

Joseph A. Henske, MD

UAMS Health
Little Rock, AR
United States

Dr. Joseph A. Henske is an associate professor of medicine and the director of the diabetes program at UAMS Health. Before joining UAMS in 2019, he worked in full-time clinical practice and served as the department chair of endocrinology for DuPage Medical Group in Chicago, IL. He currently maintains a busy clinical practice, works on several National Institutes of Health (NIH)-funded research projects, speaks at local, regional, and national meetings, and is involved in the teaching and training of resident physicians and endocrinology fellows at UAMS, both in the inpatient and outpatient settings. 

Dr. Henske’s current clinical and research interests include type 1 diabetes (T1D), type 2 diabetes (T2D), diabetes management surrounding exercise, and closed-loop automated insulin delivery systems. 

Diagnosed with T1D at the age of 15, Dr. Henske has committed his life to helping others with diabetes better manage their disease and live life to the fullest. He has been a longtime supporter of Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation) and is an advocate for increasing diabetes awareness and helping improve access to medications and technologies for patients. He also has been involved in research to one day find better ways to prevent, treat, and cure this disease. He has had a lifelong passion for running, including having completed 14 marathons, and encourages his patients to include exercise as a key component in the treatment of their diabetes. Outside the clinic he enjoys spending time with family, especially his wife Lauren and their seven children. 

Disclosures: 

  • Dr. Henske has no financial relationships to disclose. 
Vivian Fonseca

Faculty Member

Vivian Fonseca, MD, FRCP

Tulane University School of Medicine
New Orleans, LA
United States

Dr. Vivian Fonseca is professor of medicine, assistant dean for clinical research, the Tullis-Tulane alumni chair in diabetes, and chief of the section of endocrinology at Tulane University Medical Center in New Orleans, Louisiana. He is a past president for science and medicine of the American Diabetes Association (ADA; 2012) and has served on the ADA board of directors and several committees. He has served on the board of directors of the American Association of Clinical Endocrinologists (AACE) and on the board of trustees of the American College of Endocrinology. He has served on committees writing guidelines for both of these organizations. He has held a leadership role and served on various committees for several other organizations, including the American Board of Internal Medicine. He has received several awards, including the Banting Medal for Leadership and Service from the ADA, the Seale Harris award from the Southern Medical Association, and the Gerald Reaven award from the World Congress in Insulin Resistance. He has received several teaching awards, was elected to the Alpha Omega Alpha Honor Medical Society, and has been listed for several years among the best doctors in the United States and for several years rated by Expertscape among the top 10 experts in diabetes worldwide. Dr. Fonseca is a fellow of the Royal College of Physicians (London). 

Dr. Fonseca plays a significant role in clinical research as assistant dean at Tulane University and in its partnership with the Louisiana Clinical and Translational Science (LACaTS) program. He has served as associate director of the Aging and Cardiometabolic COBREs and is a mentor and committee member in Building Interdisciplinary Research Careers in Women’s Health (BIRCWH). He has a strong interest in facilitating clinical research and developing the next generation of translational researchers. He is the medical director of the Tulane Clinical Trials Unit and director of the research professional development core, which runs the Master of Science in Clinical Research degree course. 

Dr. Fonseca’s research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease, particularly on the role of inflammation and other novel risk factors. He has a research program evaluating inflammation in diabetes and using technology to improve diabetes care in underprivileged populations, especially the development and use of a novel diabetes risk engine (BRAVO) in clinical practice. He is co-principal investigator (PI) of REACHNET, a large network that conducts research utilizing electronic health records of more than 2 million people across several states. He is the site PI of several large national research programs, including the All of Us Program, COVID related studies – N3C utilizing electronic medical record (EMR) data about COVID, and the RECOVER study that will evaluate long-term COVID complications in a large cohort. 

Disclosures: 

  • Employee/owner: Eli Lilly, Corcept
  • Consultant/advisory board: Asahi, Bayer, Abbott, Boehringer Ingelheim, Corcept
  • Grants (paid to institution): Fractyl, Jaguar Gene Therapy
  • Stockholder: Amgen, Abbott
  • Stock options: Mellitus Health, BRAVO4Health
  • Patents pending: BRAVO risk engine for predicting diabetes complications; PAX4 gene therapy for type 1 diabetes
Anne Peters

Faculty Member

Anne Peters, MD

Keck School of Medicine, USC
Los Angeles, CA
United States

Dr. Anne Peters is a professor at the Keck School of Medicine of the University of Southern California. She runs diabetes centers in Beverly Hills and in underserved East Los Angeles. She has been a PI on multiple grants, has authored more than 250 articles and 4 books, and has given lectures around the world. Her major interests involve translating research findings, from lifestyle interventions to technology, to people with diabetes throughout the socioeconomic spectrum. She has been part of the ADA/EASD writing group on the management of type 2 diabetes, is the co-chair for the ADA/EASD writing group for the treatment of type 1 diabetes, is a member of the Professional Practice Committee writing the ADA Standards of Care, and is the chair of the Endocrine Society Technology Guideline writing group. She was awarded the ADA Outstanding Physician Clinician Award, the Bernardo Alberto Houssay Award from the National Minority Quality Forum, and the Laureate Award for Public Service from the Endocrine Society. 

Disclosures: 

  • Grants: Abbott Diabetes Care, Dexcom, Insulet
  • Consultant/advisory board: Abbott Diabetes Care, Medscape, Vertex, Zealand
  • Stock ownership/stock options: Omada Health, Teladoc (past)
Close